|
|
 |
|
Viewing report
|
|
|
|
HIV Market Forecast
Datamonitor, July 2010
This report explores key issues in HIV across the US and five major EU markets (France, Germany, Italy, Spain, and the UK). It contains an assessment of key HIV drugs, a discussion of HIV market dynamics, and a 10-year patient-based sales forecast.
Scope:
- Datamonitor’s first HIV market assessment based on patient-based forecasting (PBF) methodology.
- Analysis of HIV market dynamics across the US and five major EU markets, supported by a large physician survey and insights of key opinion leaders.
- Detailed sales forecasts for the major antiretroviral classes, molecules, and brands in the US and each of the five major EU markets.
Highlights:
- Despite cost-containment efforts and an increasing threat of generic incursion, Datamonitor expects the HIV market in the US and five major EU markets to grow to $16.5bn in 2021. Major growth drivers are a continuously rising HIV prevalent population and the launch of new pipeline drugs, particularly of new single-tablet regimens (STRs).
- Following strong growth in the first half of the forecast period (2011–16), Datamonitor expects patent expirations of key antiretrovirals and a leveling off of HIV prevalence rates. This will likely hinder HIV market growth in the US and five major EU markets from 2017 onwards, eventually leading to declining overall sales in 2021.
Reasons to buy:
- Understand the changing market dynamics of HIV drugs, success factors for leading brands and the commercial potential of late-stage pipeline products.
- Assess the impact of events such as patent expiries and new product launches on individual brands and the overall HIV antiretroviral market.
- Obtain full country, class, and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2011 to 2021.
Customers who bought this item also bought
Market and Product Forecasts: HIV - Rising prevalence and novel STRs boost sales in the US and Europe
Forecast Insight: HIV - Increasing dominance of fixed dose combinations raises bar for single agents
R&D Trends: HIV - An active pipeline faces fierce competition in the HIV market
Product Profiles: HIV - Growing number of FDCs further commoditizes the HIV market
Evolving Patterns and Unmet Needs in the TB Population in Developing and Developed Markets
HIV/AIDS Testing - Global Strategic Business Report
Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
Key Companies: HIV - Companies Co-operate and Co-formulate to Stay Competitive in a Tight HIV Market
Global HIV Drug Pipeline Capsule - 2012
Epidemiology: Peripheral Neuropathic Pain - A common co-morbidity for HIV, diabetes, and herpes zoster
|
|
|
|
